Discontinued — last reported Q3 '23
nemtabrutinib — Other Intangibles, Net
Merck & Co. nemtabrutinib — Other Intangibles, Net remained flat by 0.0% to $418.00M in Q3 2023 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
A decrease in this value typically indicates either regular amortization or an impairment charge due to unfavorable clinical trial results or market outlook, while an increase suggests additional investment or acquisition of related assets.
Detailed definition
This metric represents the net book value of intangible assets specifically associated with the nemtabrutinib product li...
Peer comparison
Comparable to 'In-Process Research and Development' or 'Product Rights' reported by other biopharmaceutical companies for specific drug candidates.
mrk_segment_nemtabrutinib_other_intangibles_netHistorical Data
| Q4 '21 | Q3 '22 | Q4 '22 | Q3 '23 | |
|---|---|---|---|---|
| Value | $2.00B | $1.20B | $418.00M | $418.00M |
| QoQ Change | — | -40.0% | -65.2% | +0.0% |
| YoY Change | — | — | -79.1% | -65.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s nemtabrutinib — other intangibles, net?
- Merck & Co. (MRK) reported nemtabrutinib — other intangibles, net of $418.00M in Q3 2023.
- What does nemtabrutinib — other intangibles, net mean?
- The net accounting value of intellectual property and development assets tied to the nemtabrutinib product line.